Clinical Trial Update: Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes [Phase 3]

View source ↗

Summary

Sanofi's Phase 3 trial evaluating cardiovascular outcomes with rimonabant has been terminated, marking an end to that study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Cardiovascular Disease | Phase 3 | Status: TERMINATED